RFP For GLP-1 Medication Access, Affordability & Management Solutions

The City of Cambridge is seeking a vendor to design, implement, and manage a direct‑to‑employer medication access program for GLP‑1 drugs (e.g., Wegovy, Zepbound). The solution must allow approximately 800 city‑eligible members to obtain these high‑cost medications through manufacturer‑direct or discounted cash‑pay channels, funded by a city contribution, without adding the drugs to the municipal pharmacy benefit. The vendor must be a licensed pharmacy‑service organization operating in Massachusetts, demonstrate partnerships with Eli Lilly’s LillyDirect and Novo Nordisk’s NovoCare programs, and provide rapid turnaround (≤5 business days for new prescriptions, ≤24 hours for refills). The contract includes data‑privacy (HIPAA), reporting, member support, and a phased pricing model with optional renewal for up to three years. • Direct‑to‑employer, city‑funded GLP‑1 medication purchase model • Serve ~800 members, ~8,000 transactions per year • Must be licensed in MA and partner with LillyDirect/NovoCare • Required turnaround: ≤5 business days (new), ≤24 hours (refill) • Provide HIPAA‑compliant data handling, aggregate reporting, and member support (phone/chat) • Contract term begins after award, with optional renewals for Years 2‑3 • Pricing to be submitted as a fixed annual program fee (no hidden costs) • Evaluation based on turnaround, member experience, MA experience, public‑sector references, and compliance with living‑wage and wage‑theft rules.